TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36655343

Group type: EXPERIMENTAL
Intervention: Rurioctocog alfa pegol prophylaxis targeting FVIII trough levels of 1-3%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rurioctocog alfa pegol prophylaxis targeting FVIII trough levels of 8-12%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emicizumab prophylaxis with assumed 20% FVIII equivalency
Number of subjects: 0
Study: 36655470

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (50 U, 100 U, or 200 U, not to exceed 6 U/kg)
Number of subjects: 95
Study: 36655712

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 54
Study: 36655731

Group type: EXPERIMENTAL
Intervention: Nocturia group (≥2 voids/night)
Number of subjects: 10190

Group type: EXPERIMENTAL
Intervention: NPBOO group (men)
Number of subjects: 10190

Group type: EXPERIMENTAL
Intervention: NPOAB group (women)
Number of subjects: 10190

Group type: COMPARATOR
Intervention: Idiopathic NP
Number of subjects: 10190
Study: 36655762

Group type: EXPERIMENTAL
Intervention: Musculoskeletal (MSK) flares
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 336
Study: 36655976

Group type: EXPERIMENTAL
Intervention: T follicular helper (Tfh) cells
Number of subjects: 0
Study: 36656302

Group type: EXPERIMENTAL
Intervention: Osimertinib treatment
Number of subjects: 3014
Study: 36656461

Group type: EXPERIMENTAL
Intervention: RO7297089 (60 mg to 1850 mg, administered weekly by intravenous infusion)
Number of subjects: 27
Study: 36656551

Group type: EXPERIMENTAL
Intervention: Tight Glycemic Control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 36656726

Group type: EXPERIMENTAL
Intervention: Visual Interpersonal Analog Scale (VIAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interpersonal behavior checklist
Number of subjects: 0
Study: 36656819

Group type: EXPERIMENTAL
Intervention: SLIM lifestyle intervention delivered by public health nurses
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SLIM lifestyle intervention
Number of subjects: 54
Study: 36656845

Group type: EXPERIMENTAL
Intervention: Preoperative echocardiographic findings of left ventricular dysfunction
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Preoperative echocardiographic findings of right ventricular dysfunction
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Preoperative echocardiographic findings of moderate to severe valvular lesions
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction
Number of subjects: 813
Study: 36656867

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal (GI) endoscopy and biopsy specimens studied for histopathology.
Number of subjects: 110
Study: 36657027

Group type: EXPERIMENTAL
Intervention: PPAR δ Agonism
Number of subjects: 0
Study: 36657089

Group type: EXPERIMENTAL
Intervention: 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 weeks postoperatively (NAC group)
Number of subjects: 699

Group type: COMPARATOR
Intervention: 24 weeks postoperative chemotherapy (control group)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: NAC (6 weeks preoperative chemotherapy)
Number of subjects: 699
Study: 36657109

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept therapy
Number of subjects: 10
Study: 36657323

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study: 36657324

Group type: EXPERIMENTAL
Intervention: Regional hyperthermia with cisplatin added to gemcitabine (GPH)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Gemcitabine (G)
Number of subjects: 117
Study: 36657520

Group type: EXPERIMENTAL
Intervention: Minocycline (active drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36657659

Group type: EXPERIMENTAL
Intervention: GLAD program (8-week exercise and education)
Number of subjects: 206

Group type: COMPARATOR
Intervention: OLP (4 intra-articular saline injections over 8 weeks)
Number of subjects: 206
Study: 36657661

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 61
Study: 36657751

Group type: EXPERIMENTAL
Intervention: ED-based brief smoking cessation advice, including provision of an e-cigarette and referral to local stop smoking services
Number of subjects: 972

Group type: COMPARATOR
Intervention: Provision of contact details for local stop smoking services
Number of subjects: 972
Study: 36657754

Group type: EXPERIMENTAL
Intervention: Healthcare workers tested for anti-SARS-CoV-2 N antibodies
Number of subjects: 812

Group type: COMPARATOR
Intervention: All-comer patient population tested for anti-SARS-CoV-2 N antibodies
Number of subjects: 812
Study: 36657760

Group type: EXPERIMENTAL
Intervention: Home-based resistance training exercise programme incorporating resistance band and body weight exercises.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study: 36657801

Group type: EXPERIMENTAL
Intervention: Innova lateral flow tests (LFTs) using anterior nasal (AN) swabs
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: LFTs performed on AN swabs
Number of subjects: 431

Group type: COMPARATOR
Intervention: Paired buccal LFT swabs
Number of subjects: 431
Study: 36657898

Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (HMB and placebo)
Number of subjects: 26
Study: 36657900

Group type: EXPERIMENTAL
Intervention: PPN for 5 days and then enhanced ONS until 30 days post randomization
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PPN for 5 days and then standard ONS until 30 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standard care for IV fluid administration for 5 days and then enhanced ONS until 30 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standard care for IV fluid administration for 5 days and standard ONS until 30 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no PPN, no enhanced ONS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PPN
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 36657913

Group type: EXPERIMENTAL
Intervention: Dark chocolate (70% cocoa), 40g offered during HD sessions, 3 times per week for two months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 36657920

Group type: EXPERIMENTAL
Intervention: Standardized feeding protocol
Number of subjects: 0
Study: 36657962

Group type: EXPERIMENTAL
Intervention: Heart valve centres (HVCs)
Number of subjects: 790

Group type: COMPARATOR
Intervention: Satellite centres
Number of subjects: 790
Study: 36658045

Group type: EXPERIMENTAL
Intervention: CoronaVac® (1 or 2 doses with an interval of 28 days)
Number of subjects: 162691
Study: 36658109

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 651
Study: 36658168

Group type: EXPERIMENTAL
Intervention: Low resting Pd/Pa in women
Number of subjects: 1392

Group type: COMPARATOR
Intervention: High resting Pd/Pa in women
Number of subjects: 1392

Group type: COMPARATOR
Intervention: CFR assessment in women
Number of subjects: 1392

Group type: COMPARATOR
Intervention: CFR in men
Number of subjects: 1392
Study: 36658374

Group type: EXPERIMENTAL
Intervention: High-Frequency Jet Ventilation (HFJV)
Number of subjects: 60
Study: 36658380

Group type: EXPERIMENTAL
Intervention: Increase heart rate variability (HRV) biofeedback (Osc+)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Decrease heart rate variability (HRV) biofeedback (Osc-)
Number of subjects: 165
Study: 36658425

Group type: EXPERIMENTAL
Intervention: IACS-010759
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IACS-010759 with coadministration of a histone deacetylase 6 inhibitor
Number of subjects: 40
Study: 36658543

Group type: EXPERIMENTAL
Intervention: Procalcitonin antibiotic prescribing guideline adherence
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1656

Group type: EXPERIMENTAL
Intervention: Procalcitonin antibiotic prescribing guideline adherence after discharge
Number of subjects: 1656

Group type: EXPERIMENTAL
Intervention: 100% adherence in the emergency department
Number of subjects: 1656

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed in the emergency department despite low procalcitonin
Number of subjects: 1656
Study: 36658571

Group type: EXPERIMENTAL
Intervention: Walking with light stripes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Walking to metronome beats
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline (with no cues)
Number of subjects: 15
Study: 36658607

Group type: EXPERIMENTAL
Intervention: Spa therapy associated with self-management workshops
Number of subjects: 250

Group type: COMPARATOR
Intervention: Spa therapy alone
Number of subjects: 250
Study: 36658611

Group type: EXPERIMENTAL
Intervention: Telehealth multicomponent training program plus health education program (MTHE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education program alone (HE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTHE
Number of subjects: 0
Study: 36658635

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Low-moderate intensity exercise
Number of subjects: 351
Study: 36658653

Group type: EXPERIMENTAL
Intervention: Home-based exercises supervised by a physiotherapist (inspiratory muscle training, aerobic exercises, and strength exercises) for a minimum of 6 sessions in the pre-operative period, complemented with unsupervised exercise sessions.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care with the addition of advice on health-enhancing physical activity.
Number of subjects: 160
Study: 36658663

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) in addition to treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study: 36659633

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg three times a day
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study: 36659832

Group type: EXPERIMENTAL
Intervention: Tailored adjuvant treatment based on WHO-endorsed molecular classification
Number of subjects: 590

Group type: COMPARATOR
Intervention: Standard treatment (not explicitly mentioned in the abstract)
Number of subjects: 590
Study: 36660190

Group type: EXPERIMENTAL
Intervention: M89PF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual skin care
Number of subjects: 0
Study: 36660886

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) therapy
Number of subjects: 4427

Group type: COMPARATOR
Intervention: Free pill combination therapy
Number of subjects: 4427
Study: 36661092

Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 72
Study: 36661240

Group type: COMPARATOR
Intervention: Low-dose SAB-185 (3840 units/kg)
Number of subjects: 428

Group type: COMPARATOR
Intervention: High-dose SAB-185 (10240 units/kg)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 428
Study: 36661315

Group type: EXPERIMENTAL
Intervention: Darinaparsin (300 mg/m2 over 1 hour, once daily for 5 consecutive days, per 21-day cycle)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Darinaparsin
Number of subjects: 65
Study: 36661328

Group type: EXPERIMENTAL
Intervention: AWOT (Adaptively Weighted Joint Test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CWOT (Cauchy Weighted Joint Test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AWOT and CWOT applied to PGx GWAS from Bezlotoxumab Clostridium difficile MODIFY I/II Phase 3 trials
Number of subjects: 0
Study: 36661416

Group type: EXPERIMENTAL
Intervention: Compliant initial transfusion (hemoglobin < 7 g/dL)
Number of subjects: 687
Study: 36661449

Group type: EXPERIMENTAL
Intervention: Unmet nonmedication needs (UDNs) for durable medical equipment (DME)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Unmet nonmedication needs (UDNs) for home health services (HHS)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Unmet nonmedication needs (UDNs) for follow-up medical appointments (FUAs)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Overall unmet nonmedication needs (UDNs)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Greater than median level of unmet needs
Number of subjects: 195

Group type: COMPARATOR
Intervention: Composite outcome of 90-day readmission or death
Number of subjects: 195
Study: 36661670

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 165
Study: 36662130

Group type: EXPERIMENTAL
Intervention: Serum Lp(a) concentrations (median 19.9 (8.4-76.4) mg/dL)
Number of subjects: 97
Study: 36662282

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study: 36662344

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 36662544

Group type: EXPERIMENTAL
Intervention: Personalized notifications
Number of subjects: 655

Group type: COMPARATOR
Intervention: Standard notifications
Number of subjects: 655
Study: 36662561

Group type: EXPERIMENTAL
Intervention: Empowered Survivor (ES)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Springboard Beyond Cancer
Number of subjects: 600
Study: 36662568

Group type: EXPERIMENTAL
Intervention: PEAR-002b
Number of subjects: 10
Study: 36662589

Group type: EXPERIMENTAL
Intervention: Closed-Loop Technology
Number of subjects: 0
Study: 36662635

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study: 36662723

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based first-line antiretroviral treatment (ART)
Number of subjects: 61
Study: 36662819

Group type: EXPERIMENTAL
Intervention: Combination therapy (genomically-directed combination therapies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of targeted agents and combinations of targeted therapy with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histology-specific and histology-agnostic arms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-arm and randomized designs
Number of subjects: 0
Study: 36662821

Group type: EXPERIMENTAL
Intervention: Social media-based health education program (16 minutes video on PNC, reminders to view weekly for a month)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Social media-based health education program
Number of subjects: 229

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 229
Study: 36662869

Group type: EXPERIMENTAL
Intervention: Riluzole (recommended daily oral dose for two weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 90
Study: 36662903

Group type: EXPERIMENTAL
Intervention: Acetazolamide (375 mg/day, n = 34)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 59
Study: 36669140

Group type: EXPERIMENTAL
Intervention: Interval-compressed chemotherapy with ganitumab (VDC/IE with ganitumab at cycle starts and as monotherapy once every 3 weeks for 6 months after conventional therapy)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard arm (interval-compressed vincristine/doxorubicin/cyclophosphamide alternating once every 2 weeks with ifosfamide/etoposide = VDC/IE)
Number of subjects: 298
Study: 36669143

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (anti-PD-1 antibody) + Nintedanib (pan-antiangiogenic tyrosine kinase inhibitor)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Nintedanib
Number of subjects: 30
Study: 36669146

Group type: EXPERIMENTAL
Intervention: Milademetan (260 mg once daily on days 1-3 and 15-17 every 28 days)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Milademetan (intermittent schedule)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Milademetan (overall in dedifferentiated liposarcomas)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Milademetan (overall)
Number of subjects: 107
Study: 36669148

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 195

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 195
Study: 36669360

Group type: EXPERIMENTAL
Intervention: Daratumumab plus tapered steroids
Number of subjects: 2

Group type: COMPARATOR
Intervention: Rituximab (implied as a previous treatment)
Number of subjects: 2
Study: 36669663

Group type: EXPERIMENTAL
Intervention: Active HEPA air cleaners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo HEPA air cleaners
Number of subjects: 0
Study: 36669727

Group type: EXPERIMENTAL
Intervention: Robotic gait training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Functional clinical therapy
Number of subjects: 0
Study: 36669772

Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.2 mg/kg/wk (high-dose)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.1 to <0.2 mg/kg/wk (low-dose)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: PEG-rhGH (both doses)
Number of subjects: 1170
Study: 36669791

Group type: EXPERIMENTAL
Intervention: Intravenous V937 (dose-escalation cohorts)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intravenous V937 + pembrolizumab 200 mg every 3 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intravenous V937
Number of subjects: 103
Study: 36669839

Group type: EXPERIMENTAL
Intervention: TeamSTEPPS training program
Number of subjects: 0
Study: 36669845

Group type: EXPERIMENTAL
Intervention: ConquerFear-HK intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: BasicCancerCare control
Number of subjects: 174
Study: 36669847

Group type: EXPERIMENTAL
Intervention: PREP Plus (PREP and GRASP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PREP alone
Number of subjects: 60
Study: 36669872

Group type: EXPERIMENTAL
Intervention: Migalastat treatment for 18 months
Number of subjects: 16
Study: 36669936

Group type: EXPERIMENTAL
Intervention: C-PAP/PSV
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 200

Group type: COMPARATOR
Intervention: High Flow Nasal Oxygen (HFNO)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Barotrauma
Number of subjects: 200
Study: 36670050

Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Blood glucose monitoring (BGM)
Number of subjects: 104
Study: 36670100

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination in patients treated with immunotherapy (IO)
Number of subjects: 51
Study: 36670295

Group type: EXPERIMENTAL
Intervention: Psychological intervention consisting of three sessions conducted by a clinical psychologist
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 36670365

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 20
Study: 36670376

Group type: EXPERIMENTAL
Intervention: Behaviourally-informed invitation letter
Number of subjects: 21876

Group type: COMPARATOR
Intervention: Standard letter with no reminder
Number of subjects: 21876

Group type: EXPERIMENTAL
Intervention: Behavioural letter with no reminder
Number of subjects: 21876

Group type: EXPERIMENTAL
Intervention: Standard letter with reminder
Number of subjects: 21876

Group type: EXPERIMENTAL
Intervention: Behavioural letter with reminder
Number of subjects: 21876

Group type: EXPERIMENTAL
Intervention: Reminder SMS or email
Number of subjects: 21876
Study: 36670384

Group type: EXPERIMENTAL
Intervention: Education to keep the abdomen relaxed during Pilates exercises
Number of subjects: 152

Group type: COMPARATOR
Intervention: Guidance on the specific activation of the center of strength (control group)
Number of subjects: 152
Study: 36670441

Group type: EXPERIMENTAL
Intervention: DAPT for 36 months
Number of subjects: 2106

Group type: COMPARATOR
Intervention: DAPT for 12 months
Number of subjects: 2106
Study: 36670471

Group type: EXPERIMENTAL
Intervention: Balanced von Willebrand factor (1:1 vWF and FVIII) in addition to platelet transfusion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Platelet transfusion alone
Number of subjects: 120
Study: 36670495

Group type: EXPERIMENTAL
Intervention: PHYCOCARE® (phycocyanin) during oxaliplatin-based chemotherapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo during oxaliplatin-based chemotherapy
Number of subjects: 110
Study: 36670877

Group type: EXPERIMENTAL
Intervention: YPL-001
Number of subjects: 0
Study: 36671553

Group type: EXPERIMENTAL
Intervention: Novel hominid-specific IAPP isoforms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36672386

Group type: EXPERIMENTAL
Intervention: Next-Generation Sequencing (NGS) implementation for AML diagnosis
Number of subjects: 2668

Group type: EXPERIMENTAL
Intervention: Standardized NGS studies
Number of subjects: 2668
Study: 36672947

Group type: EXPERIMENTAL
Intervention: MedDiet + MAB juice
Number of subjects: 24

Group type: COMPARATOR
Intervention: MedDiet
Number of subjects: 24
Study: 36673773

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Family Psychoeducation (MBFPE)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ordinary Family Psychoeducation (FPE)
Number of subjects: 65
Study: 36673939

Group type: EXPERIMENTAL
Intervention: Sophrology/NLP intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36673992

Group type: EXPERIMENTAL
Intervention: Initial intervention engagement (number of completed counseling sessions)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: White participants
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) use during the initial intervention
Number of subjects: 372
Study: 36674120

Group type: EXPERIMENTAL
Intervention: Myofascial release with Findings-Oriented Orthopedic Manual Therapy (OMT) combined with Foam Roller (FR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Foam Roller (FR) alone
Number of subjects: 29
Study: 36674197

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation stretching (PNF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Foam Rolling (FR)
Number of subjects: 80
Study: 36675009

Group type: EXPERIMENTAL
Intervention: Dietary habits of active Crohn's disease patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Blood levels in active Crohn's disease patients
Number of subjects: 54